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The safety and protective efﬁcacy of a new one dose combination vaccine containing Porcine Circovirus
type 2 (PCV2) and M. hyopneumoniae antigens – Porcilis PCV M Hyo - was evaluated in laboratory stud-
ies and under ﬁeld conditions. Vaccination resulted in a moderate temperature increase on the day of
vaccination and mild systemic and local reactions were found in only a low percentage of the vaccinated
pigs. The local reactions observed were small (max. 2 cm) and transient (max. 1 day). In short term (onset
of immunity) and long term (duration of immunity) challenge studies with the individual pathogens, the
vaccine signiﬁcantly reduced the PCV2 load in lymphoid tissue and lungs andM. hyopneumoniae-induced
lung lesions. In a placebo-controlled ﬁeld trial on a farm where both PCV2 and M. hyopneumoniae were
present, vaccination of piglets at 3 weeks of age resulted in a reduction of PCV2 viremia and shedding and
lower lung lesion scores at slaughter. In addition, a positive effect on the average daily weight gain (+ 34
g/day) in the ﬁnishing phase was observed. It can therefore be concluded that this new ready to use com-
bination vaccine is safe and efﬁcacious against PCV2 and M. hyopneumoniae single and combined
infections.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumo-
niae are the two most prevalent pathogens encountered in today’s
pig industry. PCV2 was originally identiﬁed as the causative agent
of the ‘‘Postweaning Multisystemic Wasting Syndrome’’, but is also
involved in a number of other disease syndromes which have
been collectively named Porcine Circovirus Diseases (PCVD) [1,2].
The most pronounced PCVDs are Porcine Respiratory Disease
Complex (PRDC), Porcine Dermatopathy and Nephropathy
Syndrome, reproductive failure, granulomatous enteritis, congeni-
tal tremors and exudative epidermitis. Subclinical PCV2 infections
are characterized by poor growth performance in apparently
healthy pigs [3–5]. Considering that up to 100% of pigs are seropos-
itive for PCV2 at the time of slaughter, subclinical PCV2 infection is
currently considered to be the major form of PCVD [4,5].
M. hyopneumoniae is a respiratory pathogen in pigs and is the
primary causative agent of enzootic pneumonia (EP), a chronic dis-
ease in pig herds [6,7].M. hyopneumoniae in association with other
bacterial and viral agents is also implicated in the PRDC. EP and
PRDC cause important economic losses to the swine industry dueto reduced performance (growth rate, feed conversion ratio) and
increased antibiotic use [7].
Vaccines against PCV2 [8,9] and M. hyopneumoniae [10,11] are
routinely used in the pig industry, and it has been shown that con-
current vaccination with PCV2 andM. hyopneumoniae vaccines can
provide protection against both pathogens under laboratory condi-
tions [12]. However, for the convenience of the user and to reduce
the number of injections given to piglets, a ready-to-use combina-
tion product, preferably given as a one dose regimen, would be
highly desirable. Therefore, the objective of the present studies
was to evaluate the efﬁcacy and safety of a new ready-to-use com-
bination product based on the M. hyopneumoniae monovalent vac-
cine M+PAC (MSD Animal Health) and the PCV vaccine Porcilis
PCV (MSD Animal Health) under laboratory and ﬁeld conditions.
2. Materials and methods
2.1. Vaccine
A vaccine containing inactivated M. hyopneumoniae cells,
baculovirus-expressed ORF2 antigen of PCV2 and the Emunade
adjuvant (Porcilis PCV M Hyo, MSD Animal Health) was tested.
Emunade is a combination of an oil-in-water emulsion with
aluminium hydroxide. The vaccine was given intramuscularly as a sin-
gle 2 ml dose to 3 week old piglets according to the product leaﬂet.
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2.2.1. Laboratory study
Two groups of 12 healthy SPF pigs were either vaccinated with
Porcilis PCV M Hyo at 19–21 days of age (vaccine group) or
injected with phosphate buffered saline (control group). Until
14 days post vaccination (dpv), the piglets were observed daily
for abnormal systemic and local reactions. Rectal temperature
was recorded one day before vaccination, just before vaccination,
4 h after vaccination and daily for four days. At 14 dpv, all animals
were sacriﬁced for examination of the injection site.2.2.2. Field study
A GCP ﬁeld safety study was done in young piglets according to
a randomized and blinded design in two pig farms in The
Netherlands and one in Germany. In each farm, at least 56 healthy
three-week-old suckling piglets aged 17–24 days were allocated
randomly to one of two groups. The piglets in one group (vaccine)
were vaccinated with Porcilis PCV M Hyo and the piglets in the
other group (control) were injected with sterile buffered saline.
The general health of the piglets was checked at admission (one
day before vaccination), just before vaccination, 1 and 4 h after
vaccination and daily for 14 days. One day before vaccination, just
before vaccination, 4 h after vaccination and daily for 4 days after
vaccination, the rectal temperature of all piglets was measured.
The injection site was examined for local reactions by palpation
at 1 and 4 h after vaccination and then daily for 14 days. All study
piglets were weighed individually at admission (day-1) and at the
end of the study 3 weeks post vaccination (wpv).2.3. Efﬁcacy studies
2.3.1. Laboratory studies
The onset of immunity (OOI) and duration of immunity (DOI)
for each of the two vaccine antigens were determined in experi-
mental challenge studies (Table 1). In each experiment, 3 week
old pigs from herds free of M. hyopneumoniae and seropositive
for PCV2 were randomly divided in two groups (vaccine and con-
trol) at the time of vaccination. Blood samples were taken just
before vaccination, at the time of challenge and 2 (PCV2 challenge
studies only) and 3 weeks after challenge. In the DOI studies, blood
samples were also taken at regular intervals between vaccination
and challenge.
PCV2 challenge was done by intranasal instillation (3 ml per
nostril, ±106 TCID50) of a recent Dutch ﬁeld isolate at 2 wpv or
22 wpv. Three weeks after PCV2 challenge, all pigs wereTable 1
Overview of the laboratory challenge studies. Piglets were vaccinated at three weeks
of age.
Type of
study
Group No. of
piglets
Challenge at (weeks
post vaccination)
Challenge
Onset of
immunity
Porcilis PCV
M Hyo
15 2 PCV2
Control 15
Onset of
immunity
Porcilis PCV
M Hyo
19 4 M. hyopneumoniae
Control 19
Duration of
immunity
Porcilis PCV
M Hyo
15 22 PCV2
Control 15
Duration of
Immunity
Porcilis PCV
M Hyo
40 21 M. hyopneumoniae
Control 40necropsied and the mesenteric and inguinal lymph nodes, tonsil
and lung were collected for quantiﬁcation of the PCV2 viral load.
M. hyopneumoniae challenge was performed intratracheally on
two consecutive days with 10 ml of a culture of a Danish ﬁeld iso-
late (provided by Dr N. Friis, National Veterinary Laboratory,
Copenhagen) containing ±107 CCU/ml at 4 wpv or 21 wpv. Three
weeks after challenge, the pigs were necropsied to evaluate lung
lesions which were scored as described [13]; the maximum score
is 55.
During the studies, pigs were observed daily for clinical
abnormalities.
2.3.2. Field study
A GCP combined ﬁeld safety and efﬁcacy study was performed
according to a controlled, randomized and blinded design in a
French pig herd with a M. hyopneumoniae and a PCV2 infection.
Healthy three week old suckling piglets were allocated randomly,
within litters, to one of two groups of approximately 300 piglets
each. The pigs in one group (vaccine) were vaccinated with
Porcilis PCV M Hyo and the pigs in the other group (control) were
injected with sterile buffered saline. The pigs were weighed indi-
vidually at vaccination, at transfer to the ﬁnishing unit and before
slaughter. Medication was recorded and pigs that died during the
study were examined post mortem to establish the cause of death.
The lungs were examined individually at slaughter to score the
severity of typical M. hyopneumoniae lesions and pleurisy.
Twenty ﬁve piglets per treatment group were bled for serum sam-
ples and rectal and nasal swabs were taken approximately every
4 weeks. Although safety was not the primary objective of this
study, the investigator routinely observed the animals at
vaccination and, as a group, at 4 h after and 1, 4, 7 and 14 days after
vaccination. The primary efﬁcacy parameters were M. hyopneumo-
niae-like lung lesions at slaughter, PCV2 viral load in serum (PCV2
viremia) and the average daily weight gain (ADWG) during
ﬁnishing, (i.e. between 7 and 19 wpv). Secondary parameters were
overall ADWG (i.e. between vaccination and 19 wpv), mortality,
morbidity (individual medication), pleurisy lesions and PCV2
shedding. Also the serological response to vaccination or ﬁeld
infection was determined.
2.4. Serology
For M. hyopneumoniae, a commercial ELISA (IDEXX, M. hyo Ab
test) was used according to the manufacturer’s instructions.
Results were expressed as negative, positive or inconclusive
according to the product leaﬂet. For PCV2, an in-house ELISA was
performed as previously described [14].
2.5. Quantiﬁcation of PCV2 DNA
Quantiﬁcation of the PCV2 viral load in serum, lymphoid organs,
lung and excretions was performed by qPCR as previously
described [14]. In brief, viral DNA was extracted using DNA/Viral
NA SV 1.0 kit. The ampliﬁcation was performed in a reaction mix-
ture containing 10 ll extracted DNA, 1.5 ll (15 mM) of forward
primer (50-TggCCCgCAgTATTTCTgATT-30), 1.5 ll (15 mM) of reverse
primer) (50-ggggAAAgggTgACgAACTg-30), 2.0 ll (20 mM) DLHP
probe (50-FAM-CCAgCAATCA-gACCCCgTTggAATg-TAMRA-30), 5.0 ll
dNTPs (SphaeroQ), 1.0 ll SuperTaq (SphaeroQ) and 29 ll PCR buf-
fer. The reactions were performed in a real-time thermocycler with
the following cycling times: 1 cycle at 50 C for 120 s, 1 cycle at
95 C for 600 s, 40 cycles at 95 C for 15 s and at 60 C for 60 s.
To allow comparison of the viral load of different sample types
(serum, tissues, swabs) results of the viral load are expressed as
copies per ll DNA extract. During validation of the PCR, the limit
Table 2
Analysis of the safety of the PCV-M. hyopneumoniae combination vaccine.
Vaccine Control p-values
Laboratory
safety
study
Number of pigs (n) 12 12
Pigs with local reactions (%) 0 0 1.000
Pigs with macroscopically
visible local reactions at
necropsy (%)
0 0 1.000
Pigs with a systemic reaction
(%)
0 0 1.000
Rectal temperature at 4 h post
vaccination (C)
40.5 ± 0.4 39.4 ± 0.2 <0.001
Field safety
study
Number of pigs (n) 84 85
Pigs with local reactions (%) 13.1 3.5 0.0276
Pigs with a systemic reaction
(%)
6.0 4.7 0.7464
Rectal temperature at 4 h post
vaccination (C)
40.6 ± 0.6 39.5 ± 0.4 <0.0001
average daily weight gain
(g/day) during the observation
period(0–3 wk post
vaccination)
245 ± 8 248 ± 8 0.7053
Field safety
and
efﬁcacy
study
Number of pigs (n) 302 303
Pigs with local reactions (%) 1.3 0.7 0.4504
Pigs with a systemic reaction
(%)
2.6 0.7 0.0630
Average daily weight gain
(g/day) during nursery (0–7
wk post vaccination)
360 ± 4 369 ± 5 0.0839
M. Witvliet et al. / Trials in Vaccinology 4 (2015) 43–49 45of quantiﬁcation was found to be 1.6 template copies per ll DNA
extract.
2.6. Statistical analyses
In the laboratory safety study, the rectal temperatures after vac-
cination were compared in a 2-sample t-test. Rectal temperatures
in the ﬁeld safety study were analyzed using a repeated measures
ANOVA model with farm and interaction farm  treatment group
as random effects, treatment group as ﬁxed effect and mean
pre-vaccination temperature as covariate.
Lung lesion scores in challenge experiments and the qPCR data
of inguinal and mesenteric lymph nodes, lung and tonsil were ana-
lyzed by the Wilcoxon Rank Sum test. PCV2 serology data at 2 wpv
(OOI study) were analyzed by ANOVA and the serology in the time
period 0–22 wpv (DOI study) was analyzed by ANOVA for repeated
measurements. The PCV2 serology in the ﬁeld study was also ana-
lyzed by repeated measures ANOVA.
For the serum, nasal and fecal samples collected after the onset
of the PCV2 infection in the ﬁeld study, the areas under the curve
(AUC) of the qPCR data were calculated by the linear trapezoidal
rule and ranked before analysis using ANOVA with vaccination
group, production batch and their interaction as ﬁxed effects.
Lung lesion scores in the ﬁeld study were compared between the
groups using mixed model ANOVA. Vaccination group, production
batch and their interaction were included as ﬁxed effects and the0.0
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Fig. 1. Mean group anti-PCV2 antibody responses, percentage of PCV2 positive animals and mean PCV2 DNA load in tissue samples at necropsy in PCV2 challenge studies.
Pigs were infected at 2 or 22 weeks post vaccination.
46 M. Witvliet et al. / Trials in Vaccinology 4 (2015) 43–49sow as random effect. The proportions of pigs with pleurisy (absent
or present), the mortality and the morbidity were compared
between the groups by the Cochran Mantel Haenszel method with
production batch as classiﬁcation variable. The ADWG was com-
pared between the groups using a mixed model ANOVA.
Vaccination group, production batch and gender with appropriate
interactions were included as ﬁxed effects and sow (and farm) as
a random effect. The body weight at admission was included in
the model as a covariate. The numbers of pigs with local or sys-
temic reactions and the M. hyopneumoniae serological responses
were compared with the Fisher’s exact test.
3. Results
3.1. Safety studies
Results of all safety studies are summarized in Table 2.
In the laboratory safety study, none of the animals developed
local or systemic reactions and no macroscopic abnormalities were
observed at the injection site at necropsy. At 4 hours after vaccina-
tion, the rectal temperature of vaccinated animals was on average
1.1C higher than in the control animals (p < 0.001) but returned to
normal on the day after vaccination.
In the ﬁeld safety study, treatment resulted in a local reaction
with a maximum diameter of 1 cm in 13% of the vaccinates and
0.3 cm in 4% of the controls. These local reactions were observed
at 4 hours post vaccination only and had disappeared by the next
day. The numbers of piglets with a deviation from the normalOnset of immunity (4 wpv) 
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Fig. 2. Group anti-M. hyopneumoniae seroresponse rates and median lung lesion scores a
weeks post vaccination.general health after treatment were similar in both groups (6%
and 5% for vaccinates and controls, respectively). A 1.1C higher
mean rectal temperature (p < 0.0001) at 4 hours post vaccination
was measured in the vaccinates (40.6C vs. 39.5C), which returned
to normal on the day after vaccination. Weight gain was not signif-
icantly different between groups during the three week observa-
tion period after treatment.
In the ﬁeld safety and efﬁcacy study, local reactions were
observed in approximately 1% of the pigs in both groups. The max-
imum size of the local reactions in the vaccinates was 2 cm and the
maximum duration was one day. A deviation from the normal gen-
eral health was observed in 3% of the vaccinates and 1% of the con-
trols. The animals mostly showed minor signs of discomfort 4
hours after vaccination.
3.2. Challenge studies
No clinical abnormalities that could be related to treatment
were present in the periods between vaccination and challenge.
However, some vaccinated and control pigs had lameness during
the studies, most likely due to a Streptococcus suis infection, and
in total eight vaccinates and six controls had to be euthanized for
animal welfare reasons. The PCV2 challenge infection did not result
in any clinical signs, but the qPCR data clearly showed infection of
the various lymphoid tissues and lung (Fig. 1). Mean viral loads
were in general in the order of 2-3 log10 lower in the vaccinated
pigs, and the differences between the groups were statistically sig-
niﬁcant (p < 0.05). Vaccination also resulted in a signiﬁcantlyDuraon of immunity (21 wpv) 
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M. Witvliet et al. / Trials in Vaccinology 4 (2015) 43–49 47higher antibody level against PCV2 at 2 wpv (OOI study, p < 0.0001
as well as for the 0–22 wpv period (DOI study, p < 0.0001), com-
pared to the control group that remained serologically negative
after the decline of maternal antibody titers until the time of chal-
lenge. Following challenge, vaccinates developed an anamnestic
response and the animals in the control group started to
seroconvert.
A seroresponse after vaccination was also seen in the M. hyop-
neumoniae challenge experiment with 84% of animals seropositive
at 4 wpv and 97% of animals seropositive at 21 wpv (Fig. 2). Almost
all the control animals responded serologically to the challenge
infection. At necropsy three weeks post challenge, the median M.
hyopneumoniae-induced lung lesions in the vaccinated groups
were 77% (OOI study) and 50% (DOI study) lower than in the
control groups (p < 0.05). In both of the studies, ﬁve of the
vaccinates did not have lung lesions compared to two (OOI study)
and one (DOI study) of the controls. These differences were not
statistically signiﬁcant.3.3. Field efﬁcacy study
The PCV2 serological proﬁle of the pigs in the ﬁeld study (Fig. 3)
is indicative for a PCV2 infection between 8 and 12 wpv. The mean
antibody titers of the vaccinated animals were signiﬁcantly higher
than those of the controls at 4, 8 and 12 wpv (p < 0.01). At 8 weeks
post vaccination the presence of PCV2 could be detected at low
levels in control animals reaching a peak in nasal and fecal excre-
tions at 12 wpv and in serum at 16 wpv. Compared to the control0
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Fig. 3. Mean group anti-PCV2 antibody responses, percentage of PCV2 positive animals
study. The corresponding mean areas under the curve (AUC) are presented below the inanimals the viral load of the vaccinated animals (calculated as
AUC) was signiﬁcantly reduced by 79% (p < 0.0001), 70%
(p < 0.0001) and 55% (p = 0.0159) in serum, nasal and fecal excre-
tions, respectively.
As shown in Fig. 4, 46% of vaccinated animals became M hyop-
neumoniae seropositive at 4 wpv. M. hyopneumoniae seropositive
control animals were observed at 16 wpv and coughing as a sign
ofM. hyopneumoniae infection was observed in the herd. The num-
ber of seropositive animals in the vaccinated group was signiﬁ-
cantly higher at each time point after vaccination (p < 0.01). At
slaughter, the lung lesion scores in the vaccinated group were
46% lower than in the control animals (p < 0.0001). In particular,
the percentage of animals with severe lung lesions (score >10)
was reduced by 56%. The number of animals with pleurisy was
lower in the vaccinated group (32% versus 39%), but this reduction
was not statistically signiﬁcant (p = 0.121).
Vaccination with Porcilis PCV M Hyo induced a 34 g higher
ADWG during ﬁnishing (p < 0.0001) and a 19 g higher ADWG dur-
ing the entire study period (p = 0.0019) than in the control animals
(Table 3). Although morbidity and mortality were both lower in the
vaccinated group, the differences with the controls were not statis-
tically signiﬁcant.4. Discussion
The present study supports that the new Porcilis PCV M Hyo
vaccine can safely be given to piglets of 3 weeks of age. The fre-
quency of systemic reactions was very low and as these reactions from control (p<0.05) 
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Fig. 4. Group anti-M. hyopneumoniae seroresponse rates, mean lung lesion scores at slaughter and lesion score distribution in the ﬁeld efﬁcacy study.
Table 3
Descriptive data of study animals and performance in the combined PCV2-M.
hyopneumoniae ﬁeld efﬁcacy study
Weeks post
vaccination
Vaccine Control Difference1 p-value
Number of pigs (n) Study inclusion 302 303
Number of males/
females (n)
155/
147
160/
143
Age of pigs (days) 17.9 17.9
Morbidity (%) 0–19 2.6 3.3 -0.7 0.6373
Mortality (%) 0–7 1.3 1.3 0.0 0.9960
7–19 2.7 3.7 -1.0 0.4890
0–19 4.0 5.0 -1.4 0.5563
ADWG (g/day) 0–7 360 ± 4 369 ± 4 -9 0.0839
7–19 757 ± 7 723 ± 7 +34 <0.0001
0–19 612 ± 5 593 ± 5 +19 0.0019
1 Vaccine group minus Control group
48 M. Witvliet et al. / Trials in Vaccinology 4 (2015) 43–49were also observed in the control groups that were injected with
saline, they appear to be more treatment related than a result of
vaccination. In both ﬁeld studies, the vaccinates had a slightly
lower ADWG than the controls in the nursery phase but the
differences were not statistically signiﬁcant. The local reactions
were small and transient and an average increase in the rectal
temperature of approximately 1C was observed at 4 hours post
vaccination. However, as the temperature returned to normal the
following day and as furthermore neither the general behaviornor the feed intake (as measured by body weight at 3 or 7 weeks
post vaccination in the ﬁeld studies) of the animals was affected, this
transient increase of rectal temperature can be considered to be an
acceptable vaccine related ﬁnding. This notion is supported by the
fact that an average increase of 1C is well within the limit of 1.5C
that is allowed according to European Pharmacopoeia monograph
2448 (porcine enzootic pneumonia vaccine (inactivated)).
The experimental challenge studies indicate that the onset of
immunity occurs as early as 2 weeks (PCV2) to 4 weeks (M. hyop-
neumoniae) post vaccination and lasts for at least 21 (M. hyopneu-
moniae) to 22 (PCV2) weeks. This was demonstrated by a
signiﬁcant reduction of the PCV2 viral load in lymphoid organs
and lungs and a signiﬁcant reduction of M. hyopneumoniae speciﬁc
lung lesions. Accordingly, a single vaccination of animals at 3
weeks of age may protect fattening pigs against PCV2 andM. hyop-
neumoniae infections during the production life cycle.
The observations made during the challenge experiments were
conﬁrmed in the ﬁeld efﬁcacy trial: strong reductions in PCV2 viral
load and M. hyopneumoniae-induced lung lesions were measured.
The ﬁeld efﬁcacy study showed that vaccination with Porcilis
PCV M Hyo reduced the level of the viral load of the pigs in serum
and excretions via the nasal and fecal route after infection. The
PCV2 infection encountered in the ﬁeld study was primarily
subclinical.
The serological and virological proﬁling of the animals in the
ﬁeld efﬁcacy study indicates that PCV2 infection started at approx-
imately 8 wpv and an increase in the number ofM. hyopneumoniae
M. Witvliet et al. / Trials in Vaccinology 4 (2015) 43–49 49seroresponders was observed between 12–16 wpv. Considering
that seroconversion against M. hyopneumoniae generally occurs
approximately 3-4 weeks post infection [15], the serological proﬁle
is indicative for an M. hyopneumoniae infection at around the same
time as the peak of the PCV2 infection (12–16 wpv, corresponding
to 15 to 19 weeks of age). In case of experimental dual infection
with PCV2 and M. hyopneumoniae, in which PCV2 challenge was
performed one week after M. hyopneumoniae challenge PCV2 has
been shown to potentiate the severity ofM. hyopneumoniae lesions
and M. hyopneumoniae has been shown to potentiate the severity
of PCV2 viremia [16]. The effects of a dual infection on the animal
performance are therefore usually more dramatic than with any of
the two pathogens alone. In the ﬁeld study, this is reﬂected by a 34
g higher ADWG during the ﬁnishing period (time period between
10 and 22 weeks of age).
In case of dual infections with PCV2 and M. hyopneumoniae, it
has furthermore been demonstrated that vaccination against either
one of the two pathogens alone does not reduce the severity of
infection of the respective other pathogen [16]. Consequently, vac-
cination against one of the two pathogens alone is not sufﬁcient to
protect animals from dual infections with both pathogens, high-
lighting the need and the beneﬁt of combined PCV2-M. hyopneu-
moniae vaccines.
In conclusion, this is the ﬁrst report to show that it is possible to
develop a ready-to-use PCV2 and M. hyopneumoniae vaccine that
can be given as a one dose product.
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